Hemophilia A Market to Witness Steady Growth Through 2036 Driven by Rising Disease Burden, Expanding Treatment Landscape, and Innovative Gene Therapies | DelveInsight

DelveInsight's latest "Hemophilia A Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive understanding of Hemophilia A, covering historical and forecasted epidemiology, current treatment practices, emerging therapies, market dynamics, and market size trends across the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates the impact of newly approved therapies, upcoming pipeline assets, reimbursement landscape, and evolving treatment paradigms expected to reshape the Hemophilia A market through 2036.

Hemophilia A is one of the most extensively studied inherited bleeding disorders, and the treatment landscape has evolved significantly over the past decade with the introduction of extended half-life factor VIII products, bispecific antibodies, RNA interference therapies, anti-TFPI agents, and gene therapies. DelveInsight's analysis indicates that continued innovation, improving diagnosis rates, increasing adoption of prophylactic treatment, and the commercialization of next-generation therapies are expected to drive sustained market growth during the forecast period.
Key Takeaways from the Hemophilia A Market Report

• According to DelveInsight, the Hemophilia A market in the 7MM was valued at nearly USD 13 billion in 2025 and is projected to grow steadily through 2036, driven by increasing uptake of innovative therapies and continued expansion of prophylactic treatment strategies.

• The United States accounted for the largest market share, representing nearly half of the total Hemophilia A market across the seven major markets in 2025, while the United Kingdom represented the largest market among the EU4 and the UK.

• DelveInsight estimates that the total diagnosed prevalent population of Hemophilia A in the 7MM reached approximately 49,600 cases in 2025, with the United States accounting for nearly 15,000 diagnosed cases. Disease prevalence is expected to increase gradually throughout the forecast period.

• Severe Hemophilia A continues to account for the largest proportion of diagnosed patients. Approximately 47% of diagnosed US patients had severe disease in 2025, while around 6,800 patients in the 7MM were living with inhibitors, highlighting the continued need for effective non-factor replacement therapies.

• The current treatment landscape includes established and recently approved therapies such as HEMLIBRA (emicizumab), ALTUVIIIO, HYMPAVZI, ALHEMO, ROCTAVIAN, and QFITLIA, all of which are contributing to increasing competition within the Hemophilia A market.

• The emerging pipeline remains robust, with promising late-stage candidates including Mim8 (Novo Nordisk), Giroctocogene fitelparvovec (Sangamo Therapeutics), NXT007/RG6512 (Roche/Chugai), DTX201 (Ultragenyx Pharmaceutical), and ASC-618, among others. These therapies are expected to further transform disease management over the coming decade.

• DelveInsight expects the Hemophilia A treatment paradigm to continue shifting toward less frequent dosing schedules, personalized prophylaxis, non-factor replacement therapies, and one-time gene therapies, improving long-term disease management while reducing treatment burden for patients.

Request a sample and discover the recent advances inHemophilia A treatment drugs https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Hemophilia A Market

• The Hemophilia A market is undergoing substantial transformation as healthcare providers increasingly adopt innovative treatment approaches that extend beyond traditional factor VIII replacement therapies. While recombinant factor VIII products continue to play an important role, the market is rapidly evolving with the introduction of bispecific antibodies, RNA interference therapies, anti-TFPI agents, and gene therapies that aim to provide sustained bleed protection with reduced treatment burden. These innovations are expected to improve patient adherence, enhance quality of life, and expand treatment options for both inhibitor and non-inhibitor patient populations.

• Growing awareness of inherited bleeding disorders, improved diagnostic capabilities, and wider implementation of prophylactic treatment strategies are also contributing to market expansion. Early diagnosis and preventive therapy have become increasingly important in minimizing joint damage, reducing bleeding episodes, and improving long-term clinical outcomes. The increasing preference for prophylaxis over on-demand treatment is expected to remain one of the primary growth drivers throughout the forecast period.

• Recent regulatory approvals continue to reshape the competitive landscape. Newly approved therapies, including QFITLIA, HYMPAVZI, ALHEMO, ALTUVIIIO, and ROCTAVIAN, have significantly expanded therapeutic options for patients with Hemophilia A. At the same time, multiple late-stage pipeline candidates are progressing through clinical development, further strengthening future market potential. Notably, Mim8 has demonstrated encouraging clinical performance, while several gene therapy programs continue advancing toward regulatory submissions, highlighting the industry's commitment to developing longer-lasting and potentially disease-modifying treatments.

• Despite these advances, several challenges continue to influence market dynamics. High treatment costs, uncertainty surrounding the long-term durability of gene therapies, pricing pressures from healthcare systems, and anticipated biosimilar competition remain important considerations for stakeholders. Nevertheless, continuous scientific innovation, favorable regulatory activity, and increasing investment in novel therapeutic platforms are expected to sustain positive market momentum through 2036.

Hemophilia A Market Analysis

• According to DelveInsight's assessment, the Hemophilia A market across the seven major markets is expected to witness steady growth during the forecast period (2022-2036), primarily driven by increasing diagnosis rates, growing adoption of prophylactic treatment, continuous therapeutic innovation, and the anticipated launch of multiple emerging therapies. The market is transitioning from conventional factor VIII replacement therapies toward novel non-factor replacement approaches and gene therapies designed to reduce treatment burden while providing durable bleed protection.

• The treatment paradigm for Hemophilia A has evolved considerably over the past several years. Historically, recombinant and plasma-derived factor VIII replacement products formed the cornerstone of disease management. However, recent approvals of innovative therapies-including HEMLIBRA (emicizumab), ALTUVIIIO, HYMPAVZI (marstacimab), ALHEMO (concizumab), ROCTAVIAN (valoctocogene roxaparvovec), and QFITLIA (fitusiran)-have significantly diversified treatment options for patients with and without inhibitors. These therapies provide improved efficacy, extended dosing intervals, and greater convenience, resulting in increasing physician and patient preference for prophylactic treatment strategies.

• DelveInsight estimates that the total Hemophilia A market across the 7MM was valued at nearly USD 13 billion in 2025, with the United States accounting for approximately half of the overall market. Within Europe, the United Kingdom represented the largest individual market, while Japan continued to maintain a significant share owing to established diagnosis and treatment practices. Increasing adoption of newly approved therapies and continued expansion of eligible patient populations are expected to support market growth through 2036.

• The competitive landscape has become increasingly dynamic following multiple regulatory approvals during the past few years. The emergence of extended half-life recombinant factor VIII products, bispecific antibodies, RNA interference therapies, anti-TFPI antibodies, and gene therapies has intensified competition across both inhibitor and non-inhibitor patient populations. While traditional recombinant FVIII therapies remain widely prescribed, market share is expected to gradually shift toward therapies offering superior convenience, less frequent administration, and sustained efficacy.

• Furthermore, gene therapy continues to represent one of the most transformative developments in Hemophilia A management. One-time treatment approaches such as ROCTAVIAN have demonstrated the potential to fundamentally alter disease management by reducing long-term dependence on chronic prophylactic therapy. Alongside gene therapy, next-generation bispecific antibodies and RNA interference therapies are expected to further strengthen competition and accelerate innovation throughout the forecast period.

• Despite these positive developments, market expansion continues to face several challenges, including high treatment costs, uncertainty surrounding long-term durability of gene therapies, reimbursement hurdles, and expected pricing pressure from healthcare systems. Nevertheless, continued investment in innovative technologies and increasing clinical confidence in newer treatment modalities are anticipated to sustain favorable market growth over the next decade.
Competitive Landscape

• The Hemophilia A therapeutic landscape is highly competitive and continues to evolve with the introduction of novel therapies targeting different mechanisms of action. Recent approvals have expanded treatment choices beyond conventional factor VIII replacement therapy, allowing physicians to individualize treatment based on disease severity, inhibitor status, age, treatment preference, and patient lifestyle.

• Currently marketed therapies include HEMLIBRA (Roche/Chugai), ALTUVIIIO (Sanofi/Sobi), HYMPAVZI (Pfizer), ALHEMO (Novo Nordisk), ROCTAVIAN (BioMarin), and QFITLIA (Sanofi/Alnylam Pharmaceuticals). These therapies complement existing recombinant and plasma-derived factor VIII products and continue to reshape prescribing patterns across the seven major markets.

• The competitive environment is expected to become even more dynamic with the anticipated commercialization of several late-stage pipeline candidates. DelveInsight expects increasing competition among bispecific antibodies, RNA interference therapies, anti-TFPI therapies, and gene therapies as developers seek to improve efficacy, reduce dosing frequency, enhance patient convenience, and deliver durable clinical benefit.

Dive deep into rich insights for new drugs for Hemophilia treatment, visit https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Emerging Therapies Transforming the Hemophilia A Treatment Landscape

Several pharmaceutical and biotechnology companies are actively developing innovative therapies that have the potential to redefine future treatment strategies for Hemophilia A.

Mim8 (denecimig) - Novo Nordisk
Mim8 is a next-generation FVIIIa mimetic bispecific antibody designed for once-weekly or once-monthly prophylactic treatment in patients with Hemophilia A, irrespective of inhibitor status. Administered subcutaneously, Mim8 bridges activated Factor IX and Factor X to restore thrombin generation by functionally replacing missing factor VIII activity. In September 2025, Novo Nordisk submitted a Biologics License Application to the US FDA for Mim8 for routine prophylaxis in adults and pediatric patients with Hemophilia A.

NXT007/RG6512 - Roche/Chugai
NXT007 is a next-generation bispecific antibody engineered to build upon the clinical success of HEMLIBRA. Developed using Chugai's proprietary antibody engineering technologies, the therapy is designed to provide improved coagulation activity, enhanced pharmacokinetics, and greater treatment convenience. Regulatory submission is anticipated later in the forecast period.
Other important pipeline assets include Giroctocogene fitelparvovec (SB-525) from Sangamo Therapeutics, DTX201 (Peboctocogene camaparvovec) from Ultragenyx Pharmaceutical, and ASC-618 from ASC Therapeutics. Collectively, these investigational therapies represent diverse therapeutic approaches, including gene therapy and advanced biologics, with the potential to substantially reduce bleeding episodes while improving long-term disease management.

Learn more about the novel and emerging Hemophilia therapies https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments

The Hemophilia A pipeline continues to witness significant regulatory and clinical milestones that are expected to influence future market dynamics.
• February 2026: Pfizer announced that the US FDA accepted and granted Priority Review to the supplemental Biologics License Application for HYMPAVZI (marstacimab) to expand its indication to include Hemophilia A or B patients aged six years and older with inhibitors, as well as pediatric patients without inhibitors.
• December 2025: Novo Nordisk presented positive Phase III FRONTIER2 data demonstrating that Mim8 achieved sustained bleed reduction over 52 weeks in adolescents and adults with Hemophilia A, including patients with factor VIII inhibitors.
• November 2025: GeneVentiv Therapeutics reported a positive FDA meeting supporting progression of GENV-HEM into first-in-human clinical studies following confirmation of its IND-enabling development strategy.
• January 2025: Metagenomi Therapeutics announced continued advancement of MGX-001, highlighting encouraging preclinical data demonstrating dose-dependent factor VIII activity and favorable genome editing specificity in non-human primate studies.

DelveInsight anticipates that continued clinical progress, regulatory approvals, and commercialization of innovative therapies will further strengthen competition while expanding treatment opportunities for patients living with Hemophilia A across the seven major markets throughout the forecast period.

What is Hemophilia A?

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency or absence of coagulation Factor VIII (FVIII), a protein essential for normal blood clot formation. The disorder is primarily inherited in an X-linked recessive pattern and predominantly affects males, while females are generally carriers, although some may also experience bleeding symptoms. Depending on the level of functional Factor VIII activity, Hemophilia A is categorized into mild, moderate, and severe disease, with severe patients experiencing spontaneous bleeding episodes that may lead to progressive joint damage, disability, and reduced quality of life if left untreated.

The principal objective of Hemophilia A management is to prevent bleeding episodes, preserve joint function, and improve long-term clinical outcomes. Over the past decade, treatment has evolved significantly from conventional plasma-derived and recombinant Factor VIII replacement therapies to innovative prophylactic approaches, including bispecific antibodies, anti-TFPI therapies, RNA interference therapies, and gene therapy. These advancements are enabling less frequent dosing schedules, improved patient convenience, and the potential for long-term disease control.
Patients with severe Hemophilia A remain at increased risk of developing neutralizing antibodies (inhibitors) against Factor VIII replacement therapy, creating significant therapeutic challenges. Approximately 30% of patients with severe disease develop inhibitors, reducing the effectiveness of conventional replacement therapies. Consequently, treatment strategies have expanded to include bypassing agents, immune tolerance induction (ITI), and newer non-factor replacement therapies such as HEMLIBRA, ALHEMO, HYMPAVZI, and QFITLIA.

The future treatment landscape is expected to continue shifting toward personalized prophylaxis, extended half-life therapies, bispecific antibodies, RNA interference therapies, and gene therapies capable of providing durable clotting factor expression while minimizing treatment burden.

Learn more about Hemophilia A Market Hemophilia A Market
Report
https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth assessment of disease epidemiology, current treatment practices, marketed products, emerging therapies, market trends, pricing analysis, reimbursement landscape, patient journey, key opinion leader perspectives, and forecasted market opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The report provides comprehensive analyses of diagnosed prevalent cases segmented by geography, age, disease severity, and inhibitor status, along with detailed evaluations of marketed therapies, pipeline candidates, therapy uptake projections, pricing assumptions, and market forecasts from 2022 through 2036. In addition, the report includes competitive benchmarking, SWOT analysis, market access and reimbursement assessment, and strategic insights to support decision-making for pharmaceutical companies, investors, healthcare providers, and other stakeholders.

Hemophilia A Epidemiology Segmentation

The Hemophilia A market report offers detailed epidemiological segmentation across the seven major markets, including:
• Total Diagnosed Prevalent Cases of Hemophilia A in the 7MM
• Country-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases (Mild, Moderate, and Severe)
• Diagnosed Prevalent Cases with Inhibitors
• Diagnosed Prevalent Cases without Inhibitors
• Treatment-eligible Patient Population
• Country-wise Epidemiology Forecast (2022-2036)

According to DelveInsight's estimates, approximately 49,600 diagnosed prevalent cases of Hemophilia A were reported across the seven major markets in 2025, with the United States accounting for nearly 15,000 diagnosed patients. Severe disease represented the largest patient subgroup, while approximately 6,800 patients were living with inhibitors during the same year. These epidemiological trends are expected to continue supporting demand for innovative prophylactic and disease-modifying therapies over the forecast period.

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology
6. Hemophilia A Market Overview
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Hemophilia A Market Outlook
14. Unmet Needs
15. SWOT Analysis
16. Key Opinion Leaders' Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Media Contact
Contact Person:
Kirti Sharma
Email:
info@delveinsight.com
Phone:
+1-469-945-7679
Website:
https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.